Advanced Proteome Therapeutics Corporation

BST:0E81 Stock Report

Market Cap: €140.0k

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Advanced Proteome Therapeutics Management

Management criteria checks 2/4

Advanced Proteome Therapeutics' CEO is Paul John Woodward, appointed in Dec 2018, has a tenure of 5.25 years. directly owns 1.15% of the company’s shares, worth €1.61K. The average tenure of the management team and the board of directors is 5.3 years and 5.3 years respectively.

Key information

Paul John Woodward

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure5.3yrs
CEO ownership1.2%
Management average tenure5.3yrs
Board average tenure5.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Paul John Woodward's remuneration changed compared to Advanced Proteome Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Apr 30 2023n/an/a

-US$2m

Jan 31 2023n/an/a

-US$1m

Oct 31 2022n/an/a

-US$126k

Jul 31 2022US$70kUS$70k

US$760k

Apr 30 2022n/an/a

US$987k

Jan 31 2022n/an/a

-US$216k

Oct 31 2021n/an/a

-US$816k

Jul 31 2021US$56kUS$56k

-US$2m

Apr 30 2021n/an/a

-US$2m

Jan 31 2021n/an/a

-US$634k

Oct 31 2020n/an/a

-US$775k

Jul 31 2020US$44kUS$44k

-US$451k

Apr 30 2020n/an/a

-US$476k

Jan 31 2020n/an/a

-US$395k

Oct 31 2019n/an/a

-US$154k

Jul 31 2019US$82kUS$30k

-US$333k

Apr 30 2019n/an/a

-US$498k

Jan 31 2019n/an/a

-US$29k

Oct 31 2018n/an/a

-US$796k

Jul 31 2018US$3kn/a

-US$745k

Compensation vs Market: Insufficient data to establish whether Paul John's total compensation is reasonable compared to companies of similar size in the German market.

Compensation vs Earnings: Paul John's compensation has increased whilst the company is unprofitable.

CEO

Paul John Woodward (61 yo)

5.3yrs

Tenure

US$70,284

Compensation

Mr. Paul John Courtney Woodward has been Chief Financial Officer and Director at Railtown AI Technologies Inc. since July 2016 and served as its President and Chief Executive Officer from August 18, 2016 u...

Leadership Team

NamePositionTenureCompensationOwnership
Paul John Woodward
President5.3yrsUS$70.28k1.15%
€ 1.6k
Kenneth Phillippe
Chief Financial Officer15yrsUS$17.77k0.49%
€ 680.6
Martin John Woodward
Secretary & Independent Director5.3yrsno data1.33%
€ 1.9k

5.3yrs

Average Tenure

61yo

Average Age

Experienced Management: 0E81's management team is seasoned and experienced (5.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Paul John Woodward
President11.8yrsUS$70.28k1.15%
€ 1.6k
Martin John Woodward
Secretary & Independent Director5.3yrsno data1.33%
€ 1.9k
David Webb
Member of Corporate Advisory Board9yrsno datano data
William Catalano
Independent Director5.3yrsno data0.75%
€ 1.1k
Cory Brandolini
Director1.3yrsno datano data
Greg Thurber
Member of Scientific Advisory Board5.8yrsno datano data
Benjamin Krantz
Directorno datano datano data
Ravi Chari
Member of Scientific Advisory Board2.8yrsno datano data

5.3yrs

Average Tenure

61yo

Average Age

Experienced Board: 0E81's board of directors are considered experienced (5.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/03/04 11:13
End of Day Share Price 2023/12/06 00:00
Earnings2023/04/30
Annual Earnings2022/07/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Advanced Proteome Therapeutics Corporation is covered by 0 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution